MediRox AB of Nyköping at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Manufacturers

MediRox AB

Studsvik, 611 82 Nyköping
Sweden

Telephone +46 155 454410
info@medirox.se

This company is co-exhibitor of
Business Sweden The Swedish Trade & Invest Council

Hall map

MEDICA 2017 hall map (Hall 3A): stand 3AE29

Fairground map

MEDICA 2017 fairground map: Hall 3A

Our range of products

Product categories

  • 03  Diagnostics
  • 03.03  Haematology / Histology / Cytology
  • 03.03.07  Haemostasis reagents (coagulation)

Haemostasis reagents (coagulation)

Our products

Product category: Haemostasis reagents (coagulation)

Haemostasis

MediRox aims to continuously innovate the highest quality products and solutions for scientists and clinicians to analyse and treat haemostasis.

What is haemostasis?
Haemostasis is how the delicate balance of blood flow in our vessels is maintained. If the balance is disturbed thrombosis or bleeding might occur.

What are the risks?
When a wound arises in a vessel wall, a clot must form at the site of the injury to prevent bleeding. The first reaction in this process is vasoconstriction, where the muscles in the vessel wall contract to decrease the blood flow and the amount of blood loss. The exposure of endothelium cells recruit platelets, the smallest cell fragments in the blood. The activated platelets connect and attach themselves to each other via pseudopods,  and those clumps of platelets attach themselves to the site of injury with collagen. (This is known as the von Willebrand factor) They then use fibrinogen to form a temporary plug. In the third step the temporary plug is strengthened by the formation of a fibrin network together with other blood cells, creating a more stable clot. This stable clot stops the bleeding and activates the wound to start healing the cell walls. Finally, fibrinolysis sets in at the same time as the wound is healing. This is the normal procedure during a haemorrhage – the entire process prevents bleeding whilst simultaneously creating a sufficient clot.

Disturbance in the blood and in the vascular system may cause cardiovascular diseases. Some of the known risk factors are high blood pressure, high cholesterol, diabetes, smoking, and family history. Many cardiovascular diseases can be prevented by changing lifestyle, e.g. quitting smoking, maintaining a healthy BMI, exercising regularly, eating healthily, and reducing stress.

A disturbed blood balance eventually results in bleeding or thrombosis. If the blood is diluted, it is impossible for a clot formation to form, and blood loss is an inevitable result if there is an injured vessel wall. This event might be caused by haemophilia, a deficiency of coagulation factors, or thrombocytopenia, which is a low number of platelets.

If the blood throughout the vessel has a high viscosity, and the blood flow is substantial decreased due to a thrombosis, and if this takes place in a coronary vessel that supplies the heart with oxygen, angina pectoris will most likely occur.

The cause of cardiovascular diseases and thrombosis are most often due to inflammation in the vascular system, a process called arteriosclerosis. The inflammation gives incorrect signals to the blood that there might be a haemorrhage in the vessel wall and will probably result in an unrestrained thrombus. In this case, the affected person is at high risk of an embolism, and will most likely be perscribed oral anticoagulants, such as warfarin or NOAC’s/DOAC’s. Monitoring the drug dose is crucial in patient treatment as the side effects of anticoagulant therapy include excessive bleeding. The patient needs to visit the care centre at least every other month to have the PT-INR measured, which determines the anticoagulant concentration in the blood. INR can be determined by two methods, either PT Owren’s or PT Quick.

More Less

About us

Company details

Leading haemostasis diagnostics products
MediRox develops, manufactures and markets reagents, controls and calibrators for improved efficiency in haemostasis diagnostics.

MediRox produces high quality control plasmas and diagnostic reagents such as PT, APTT, AT, TT, Fib Clauss and D-Dimer within the field of haemostasis.

More Less